Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREPTO VAC I: wSp Vaccine Safety in Healthy Adults
NCT07059182Phase 1Completed
- Sponsor
- Serum Life Sciences
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial in pneumococcal disease and acute otitis media (AOM) (2 arms), sponsored by Serum Life Sciences. Primary endpoint: Safety and tolerability outcome at 30 days. Started Jun 2025; status: completed.
02
Conditions
pneumococcal diseaseacute otitis media (AOM)
Beyond the preview
Go deeper on NCT07059182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059182.